

Scientific Advisory Board appointment

Highlights

- Dr. Fred K Chen, a leading academic ophthalmologist from the Lions Eye Institute (Perth, Western Australia) with a special interest in inherited retinal diseases, has been appointed to PYC's Scientific Advisory Board
- Dr. Chen will also be the founding member of PYC's Ophthalmology Clinical Advisory Board as PYC moves to clinical evaluation of RNA therapeutics for inherited retinal diseases

13 September 2019: Phylogica Limited trading as PYC Therapeutics (ASX: PYC) 'The Company' or 'PYC' is pleased to announce the appointment of Dr. Fred K Chen to PYC's Scientific Advisory Board (SAB). In addition to joining the SAB, Dr. Chen will also be the founding member of PYC's Ophthalmology Clinical Advisory Board – a specialist advisory board with the objective of guiding PYC's ophthalmology pipeline through clinical evaluation.

Dr. Chen leads the Ocular Tissue Engineering Laboratory – PYC's main collaborator within the Lions Eye Institute. Commenting on the appointment, PYC CEO Dr. Rohan Hockings said 'We are enjoying working with Dr. Chen and his team at the Lions Eye Institute and are grateful for their support as we move rapidly together towards the clinical evaluation of RNA therapeutics for inherited retinal diseases'.

About Dr. Fred K Chen

Dr Chen is a clinician-scientist in retinal diseases. He qualified as an ophthalmic surgeon through the Royal Australian and New Zealand College of Ophthalmologists in 2007. Upon completion of PhD in cell transplantation in retinal diseases at University College of London and a surgical and medical retina fellowship at Moorfield Eye Hospital, London, he returned to take up a consultant vitreoretinal surgeon position at Royal Perth Hospital and Lions Eye Institute (2011-current). He established the Ocular Tissue Engineering Laboratory to develop personalized treatment in retinal degeneration. He was an NHMRC Early Career Fellow (2013-2016) and is currently an MRFF Career Development Fellow (2018-2021). He has been principal and associate investigators for 20 industry sponsored clinical trials. He has over 130 publications in peer-reviewed journals covering clinical ophthalmology, biomedical engineering, computer science, ocular genetics and stem cells. He is recognised nationally and internationally for his expertise in inherited retinal diseases, stem cell disease modelling, retinal image grading, and clinical trial design and endpoint analysis.

ENDS For further information, please contact:

INVESTORS
Rohan Hockings
CEO
Rohan.hockings@pyctx.com

About PYC Therapeutics

Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome 'the delivery challenge' and provide access for a wide range of potent and precise drug 'cargoes' to the 'undruggable genome' – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

Phylogica Limited trading as PYC Therapeutics

ACN 098 391 961